Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Clinical trial NCT03847428 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03847428
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-29
- Primary completion
- 2026-05-15
- Enrollment
- 908
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.